Cargando…

Interferon Treatments for SARS-CoV-2: Challenges and Opportunities

Interferon (IFN) therapies are used to treat a variety of infections and diseases and could be used to treat SARS-CoV-2. However, optimal use and timing of IFN therapy to treat SARS-CoV-2 is not well documented. We aimed to synthesize available evidence to understand whether interferon therapy shoul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jhuti, Diya, Rawat, Angeli, Guo, Christina M., Wilson, Lindsay A., Mills, Edward J., Forrest, Jamie I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022612/ https://www.ncbi.nlm.nih.gov/pubmed/35445964 http://dx.doi.org/10.1007/s40121-022-00633-9

Ejemplares similares

Wastewater surveillance of SARS-CoV-2 in Bangladesh: Opportunities and challenges
por: Haque, Rehnuma, et al.
Publicado: (2022)

SARS-CoV-2 and interferon blockade
por: Diamond, Betty, et al.
Publicado: (2020)

SARS-CoV-2 Infection and Oral Health: Therapeutic Opportunities and Challenges
por: Coke, Christopher J., et al.
Publicado: (2021)

Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV.
por: Lokugamage, Kumari G., et al.
Publicado: (2020)

Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV
por: Lokugamage, Kumari G., et al.
Publicado: (2020)

Opportunities and Challenges in Targeting the Proofreading Activity of SARS-CoV-2 Polymerase Complex
por: Deval, Jerome, et al.
Publicado: (2022)

The early interferon catches the SARS-CoV-2
por: Decker, Thomas
Publicado: (2021)

Clash of the titans: interferons and SARS-CoV-2
por: Jouvenet, Nolwenn, et al.
Publicado: (2021)

SARS-CoV, MERS-CoV and SARS-CoV-2: A Diagnostic Challenge
por: Ezhilan, Madeshwari, et al.
Publicado: (2021)

SARS-CoV-2: an opportunity for hospital pharmacy
por: Claramunt García, Raquel, et al.
Publicado: (2022)

SARS–CoV-2 Immuno-Pathogenesis and Potential for Diverse Vaccines and Therapies: Opportunities and Challenges
por: McGill, Andrew R., et al.
Publicado: (2021)

The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges
por: Malik, Jonaid Ahmad, et al.
Publicado: (2022)

Evasion of Type I Interferon by SARS-CoV-2
por: Xia, Hongjie, et al.
Publicado: (2020)

Interferon Resistance of Emerging SARS-CoV-2 Variants
por: Guo, Kejun, et al.
Publicado: (2021)

Interferon resistance of emerging SARS-CoV-2 variants
por: Guo, Kejun, et al.
Publicado: (2022)

Potential of Interferon Lambda as an Inhibitor of SARS-CoV-2
por: Oleinik, L. A., et al.
Publicado: (2023)

Mechanisms of impairment of interferon production by SARS-CoV-2
por: Hoang, Huy-Dung, et al.
Publicado: (2023)

Coronavirus 2 (SARS-CoV-2) in water environments: Current status, challenges and research opportunities
por: Ihsanullah, Ihsanullah, et al.
Publicado: (2021)

Persistence of humoral and cellular immune response after SARS-CoV-2 infection: opportunities and challenges
por: Wu, Tangchun
Publicado: (2020)

Emerging SARS-CoV-2 Variants and Subvariants: Challenges and Opportunities in the Context of COVID-19 Pandemic
por: Rahman, Smaranika, et al.
Publicado: (2022)

Evaluation of QuantiFERON SARS-CoV-2 interferon-γ release assay following SARS-CoV-2 infection and vaccination
por: Johnson, Síle A, et al.
Publicado: (2023)

Resilient Clinical Trial Infrastructure in Response to the COVID-19 Pandemic: Lessons Learned from the TOGETHER Randomized Platform Clinical Trial
por: Forrest, Jamie I., et al.
Publicado: (2022)

Interferon antagonists encoded by SARS-CoV-2 at a glance
por: Lee, Jung-Hyun, et al.
Publicado: (2022)

SARS-CoV-2 vaccines: Lights and shadows
por: Angeli, Fabio, et al.
Publicado: (2021)

Repeat SARS-CoV-2 testing models for residential college populations
por: Chang, Joseph T., et al.
Publicado: (2020)

Implementation of environmental surveillance for SARS-CoV-2 virus to support public health decisions: Opportunities and challenges
por: Medema, Gertjan, et al.
Publicado: (2020)

Challenges and Opportunities from Targeting Inflammatory Responses to SARS-CoV-2 Infection: A Narrative Review
por: Lariccia, Vincenzo, et al.
Publicado: (2020)

Superspreading events in the transmission dynamics of SARS-CoV-2: Opportunities for interventions and control
por: Althouse, Benjamin M., et al.
Publicado: (2020)

Correction to: Repeat SARS-CoV-2 testing models for residential college populations
por: Chang, Joseph T., et al.
Publicado: (2021)

SARS-CoV-2 nsp5 Exhibits Stronger Catalytic Activity and Interferon Antagonism than Its SARS-CoV Ortholog
por: Chen, Jiyao, et al.
Publicado: (2022)

Inhibition of SARS–CoV-2 by type I and type III interferons
por: Felgenhauer, Ulrike, et al.
Publicado: (2020)

Interplay between SARS-CoV-2 and the type I interferon response
por: Sa Ribero, Margarida, et al.
Publicado: (2020)

Activation and evasion of type I interferon responses by SARS-CoV-2
por: Lei, Xiaobo, et al.
Publicado: (2020)

Antiviral activities of type I interferons to SARS-CoV-2 infection
por: Mantlo, Emily, et al.
Publicado: (2020)

SARS-CoV-2 NSP12 Protein Is Not an Interferon-β Antagonist
por: Li, Aixin, et al.
Publicado: (2021)

Immune evasion of SARS-CoV-2 from interferon antiviral system
por: Min, Yuan-Qin, et al.
Publicado: (2021)

Interfering with SARS-CoV-2: are interferons friends or foes in COVID-19?
por: Zanoni, Ivan
Publicado: (2021)

Myeloid cell interferon responses correlate with clearance of SARS-CoV-2
por: Singh, Dhiraj K., et al.
Publicado: (2022)

SARS-CoV-2-mediated evasion strategies for antiviral interferon pathways
por: Oh, Soo-Jin, et al.
Publicado: (2022)

Type I interferons and SARS-CoV-2: from cells to organisms
por: Bastard, Paul, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kq723iinae1fr80hhcothq0ku1